Skip to content

US · STLNW · MEDICAL - CARE FACILITIES

Starling Oncology Inc. Wt (STLNW) intrinsic value and stock valuation

$0.02as of 2026-09-18 · Mkt cap 4.17M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Starling Oncology Inc. Wt DCF and intrinsic value

InvestorsCraft values STLNW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from STLNW’s statements →

Starling Oncology Inc. Wt Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Care Facilities Cerritos, CA, US starlingoncology.com

How the business is doing

Fiscal 2025–2021, USD

Revenue
$203T
20252021
Net income
-$-10.93T
20252021
Free cash flow
-$-27.79T
20252025
Total equity
-$-15.72T
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2021, USD
FYFYFYFYFY
Revenue$502.7T$393.4T$324.2T$252.5T$203T
Operating income-$-36.08T-$-60.12T-$-60.04T-$-71.22T-$-45.86T
Net income-$-60.61T-$-64.66T-$-83.07T$152B-$-10.93T
EPSd-$-655.98K-$-861.67K-$-1.13M$1.89K-$-164.98K
Operating cash flow-$-24.59T————
Capital expenditure-$-3.2T————
Free cash flow-$-27.79T————
Total assets$164.7T————
Total debt$104.5T————
Net debt$71T————
Total equity-$-15.72T————
Cash and short-term investments$33.6T————
Income statement
FYFYFYFYFY
Revenue$502.7T$393.4T$324.2T$252.5T$203T
Cost of revenue$433.2T$339.4T$270.5T$204.8T$165.5T
Gross profit$69.5T$54T$53.7T$47.7T$37.5T
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$105.6T$107.8T$113.9T$119.7T$82.9T
Other expenses$0.00$6.29T-$-114B-$-790B$476B
Operating expenses$105.6T$114.1T$113.7T$118.9T$83.4T
Cost and expenses$538.8T$453.5T$384.3T$323.7T$248.9T
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$11.3T$7.5T$6.78T$4.08T$320B
Depreciation and amortization$6.94T$6.29T$5.87T$4.41T$3.34T
Ebitda-$-29.14T-$-53.83T-$-54.28T-$-66.81T-$-42.52T
Operating income-$-36.08T-$-60.12T-$-60.04T-$-71.22T-$-45.86T
Total other income/expenses, net-$-24.65T-$-4.55T-$-23.07T$71.1T$34.3T
Income before tax-$-60.74T-$-64.66T-$-83.1T-$-91B-$-11.6T
Income tax expense$131B$0.00$36B-$-243B-$-671B
Net income-$-60.61T-$-64.66T-$-83.07T$152B-$-10.93T
Weighted average shares outstanding$111.3T$91.5T$90.3T$721.6B$68.1T
Weighted average diluted shares outstanding$92.4T$75T$73.7T$80.6T$66.2T
Balance sheet
FY
Cash and short-term investments$33.6T
Net receivables$59T
Inventory$16.9T
Total current assets$112.7T
Property, plant and equipment, net$33.1T
Goodwill and intangible assets$18.2T
Long-term investments$0.00
Total non-current assets$51.9T
Total assets$164.7T
Accounts payable$43.2T
Short-term debt$7.99T
Deferred revenue$0.00
Total current liabilities$71T
Long-term debt$96.6T
Deferred revenue, non-current$0.00
Total non-current liabilities$109.4T
Capital lease obligations$26.4T
Total liabilities$180.4T
Common stock$10B
Retained earnings-$-271.42T
Accumulated other comprehensive income (loss)$0.00
Total equity-$-15.72T
Total investments$0.00
Total debt$104.5T
Net debt$71T
Cash flow statement
FY
Net income-$-60.61T
Depreciation and amortization$15.3T
Stock-based compensation$4.55T
Change in working capital-$-18.31T
Accounts receivable-$-12.31T
Inventory-$-6.84T
Accounts payable$0.00
Net cash provided by operating activities-$-24.59T
Investments in property, plant and equipment-$-3.2T
Acquisitions, net$0.00
Net cash used for investing activities-$-3.07T
Common stock issued$0.00
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities$11.6T
Net change in cash-$-16.1T
Cash at end of period$33.6T
Operating cash flow-$-24.59T
Capital expenditure-$-3.2T
Free cash flow-$-27.79T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Starling Oncology Inc. Wt

        The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

        CEO
        Daniel Virnich
        Employees
        641
        Beta
        2.64

        Explore

        Frequently asked questions

        What is the intrinsic value of Starling Oncology Inc. Wt (STLNW)?

        InvestorsCraft does not currently publish an intrinsic value for STLNW. How the IC value is calculated.

        Is STLNW undervalued?

        InvestorsCraft does not publish an undervaluation signal for STLNW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.